A drug initially developed to protect skin from light and UV will soon be tested as a repigmentation therapy in vitiligo, a common disorder which causes skin to gradually lose its pigment or tone.

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with extensive vitiligo see significantly more repigmentation compared with a ...

Case reports describe repigmentation of vitiligo with facial involvement in Hispanic woman, white man (HealthDay News) — The combination of the janus kinase (JAK) 1/3 inhibitor tofacitinib and ...

Think about a world where a light is restoring your skin’s lost color. Red light therapy lamp is becoming popular for skin pigmentation treatment among people with vitiligo. Loss of pigments leads to ...

Please provide your email address to receive an email when new articles are posted on . Long-duration phototherapy should be encouraged to enhance vitiligo treatment response, with the most effective ...

It’s estimated that more than one million Americans suffer from vitiligo. The autoimmune disorder targets and destroys the pigment cells in the body, causing white patches. The FDA recently approved ...

A panel discussion that took place at the 2023 Fall Clinical Dermatology Conference focused on the importance of information to treat both vitiligo and atopic dermatitis. Atopic dermatitis (AD) and ...

Credit: Getty Images The Vitiligo Task Force developed expert-based recommendations for the treatment of vitiligo, worldwide. The International Vitiligo Task Force has issued up-to-date evidence-based ...

Dr Dunn leads a discussion outlining frontline therapies for the treatment of vitiligo. Jeffrey D. Dunn, PharmD, MBA: What therapies are being used? Are they generally covered by different books of ...

PHILADELPHIA (CBS) -- The FDA has approved a first-of-its-kind treatment for the life-altering skin condition vitiligo. It's estimated more than 1 million Americans suffer from vitiligo, which causes ...

A new cream offering hope to over 80,000 people in England living with vitiligo has been approved for NHS use. Ruxolitinib, sold under the brand name Opzelura, is the first licensed treatment to ...

Emily Kirkpatrick is a former associate style news editor at PEOPLE. She left PEOPLE in 2017. Vesnaandjic / Getty Images Vitiligo is a chronic disorder, often due to genetics or a change in the immune ...